Ascendis Pharma A (ASND) Non Operating Income (2019 - 2020)

Ascendis Pharma A has reported Non Operating Income for 8 years, with the latest figure at $213.7 million in Q4 2025.

• Quarterly Non Operating Income rose 142.83% year-over-year to $213.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $370.6 million (up 104.27% YoY) and the FY2025 annual result came in at $213.7 million, up 142.83% from the prior year.
• Non Operating Income advanced to $213.7 million in Q4 2025 per ASND's latest filing, from $88.0 million in the prior quarter.
• Over five years, Non Operating Income peaked at $213.7 million in Q4 2025 and troughed at $24.5 million in Q4 2021.
• A 5-year average of $79.0 million and a median of $40.1 million in 2023 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2022 and 2025: Non Operating Income climbed 17.47% in 2022, then jumped 142.83% in 2025.
• Over 5 years, Non Operating Income stood at $24.5 million in 2021, then advanced by 17.47% to $28.8 million in 2022, then soared by 39.49% to $40.1 million in 2023, then surged by 119.19% to $88.0 million in 2024, then jumped by 142.83% to $213.7 million in 2025.
• According to Business Quant data, Non Operating Income over the past three periods registered $213.7 million, $88.0 million, and $40.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.